Last reviewed · How we verify
Indom
At a glance
| Generic name | Indom |
|---|---|
| Also known as | Indomethacin 5 MG/ML Ophthalmic Suspension |
| Sponsor | University of Trieste |
| Target | Aldo-keto reductase family 1 member C4, Dehydrogenase/reductase SDR family member 9, Nicotinate phosphoribosyltransferase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Ankylosing spondylitis
- Bursitis
- Bursitis of shoulder
- Gout
- Osteoarthritis
- Patent ductus arteriosus
- Rheumatoid arthritis
- Shoulder Tendonitis
- Synovitis
- Tendinitis
- Tenosynovitis
Common side effects
- Headache
- Dizziness
- Dyspepsia
- Nausea
Serious adverse events
- Cardiovascular Thrombotic Events
- GI Bleeding, Ulceration and Perforation
- Hepatotoxicity
- Hypertension
- Heart Failure and Edema
- Renal Toxicity and Hyperkalemia
- Anaphylactic Reactions
- Serious Skin Reactions
- Hematologic Toxicity
- Fulminant Necrotizing Fasciitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |